Reovirus for the treatment of cellular proliferative disorders
CA 2615684 C · Owner: Lee, Patrick W. K. · Inventors: Coffey, Matthew C.; Lee, Patrick W. K.; Strong, James
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Methods for treating proliferative disorders by administering reovirus to a Ras-mediated proliferative disorder are disclosed. The reovirus is administered so that it ultimately directly contacts ras-mediated proliferating cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus serotype 1(e.g. strain Lang), serotype 2 (e.g. strain Jones) serotype 3 (e.g. strain Dearing or strain Abney) as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used as can reovirus from different species of …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 18, 2000 and granted February 14, 2017. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended February 18, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 18, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.